Trihexyphenidyl Elixir Rx
Generic Name and Formulations:
Trihexyphenidyl HCl 2mg/5mL; lime-mint flavor; contains alcohol.
Indications for Trihexyphenidyl Elixir:
Adjunct in Parkinsonism. Drug-induced extrapyramidal symptoms (EPS).
Take with food. Give in 3–4 divided doses. Parkinsonism: 1mg on day 1, may increase by 2mg every 3–5 days; usual max 6–15mg/day. Concomitant levodopa: 3–6mg/day and reduce levodopa dose. EPS: 1mg on day 1; range 5–15mg/day.
Tardive dyskinesia. Narrow-angle glaucoma.
Cardiovascular, renal, or hepatic disorders. Hypertension. Psychosis. GI or GU obstruction. Exposure to extreme heat. Monitor intraocular pressure. Avoid abrupt cessation. Nursing mothers.
Potentiates CNS depression with alcohol, CNS depressants. Antagonizes psychotropics. Additive anticholinergic effects with MAOIs. Paralytic ileus with phenothiazines, tricyclic antidepressants.
Anticholinergic and antihistaminic effects, confusion, anhidrosis, excitement, nausea, vomiting, angle-closure glaucoma, hallucinations, neuroleptic malignant syndrome, heat stroke, drowsiness.
Formerly known under the brand name Artane.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Feasibility of Clinical Production of Autologous NKG2D CAR-T
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline